285 related articles for article (PubMed ID: 15889255)
1. Tumor counterattack: fact or fiction?
Igney FH; Krammer PH
Cancer Immunol Immunother; 2005 Nov; 54(11):1127-36. PubMed ID: 15889255
[TBL] [Abstract][Full Text] [Related]
2. The influence of CD95L expression on tumor rejection in mice.
Igney FH; Behrens CK; Krammer PH
Eur J Immunol; 2003 Oct; 33(10):2811-21. PubMed ID: 14515265
[TBL] [Abstract][Full Text] [Related]
3. Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack.
Maher S; Toomey D; Condron C; Bouchier-Hayes D
Immunol Cell Biol; 2002 Apr; 80(2):131-7. PubMed ID: 11940113
[TBL] [Abstract][Full Text] [Related]
4. CD95L mediates tumor counterattack in vitro but induces neutrophil-independent tumor rejection in vivo.
Igney FH; Behrens CK; Krammer PH
Int J Cancer; 2005 Jan; 113(1):78-87. PubMed ID: 15386427
[TBL] [Abstract][Full Text] [Related]
5. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape.
Hahne M; Rimoldi D; Schröter M; Romero P; Schreier M; French LE; Schneider P; Bornand T; Fontana A; Lienard D; Cerottini J; Tschopp J
Science; 1996 Nov; 274(5291):1363-6. PubMed ID: 8910274
[TBL] [Abstract][Full Text] [Related]
6. Humoral immunodeficiency in chronic lymphocytic leukemia: role of CD95/CD95L in tumoral damage and escape.
Sampalo A; Brieva JA
Leuk Lymphoma; 2002 Apr; 43(4):881-4. PubMed ID: 12153179
[TBL] [Abstract][Full Text] [Related]
7. Cutting edge: the tumor counterattack hypothesis revisited: colon cancer cells do not induce T cell apoptosis via the Fas (CD95, APO-1) pathway.
Favre-Felix N; Fromentin A; Hammann A; Solary E; Martin F; Bonnotte B
J Immunol; 2000 May; 164(10):5023-7. PubMed ID: 10799856
[TBL] [Abstract][Full Text] [Related]
8. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil R; Egle A; Villunger A
Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
[TBL] [Abstract][Full Text] [Related]
9. The Fas counterattack: cancer as a site of immune privilege.
O'Connell J; Bennett MW; O'Sullivan GC; Collins JK; Shanahan F
Immunol Today; 1999 Jan; 20(1):46-52. PubMed ID: 10081230
[No Abstract] [Full Text] [Related]
10. Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumor-immune conflict.
O'Connell J; Bennett MW; Nally K; Houston A; O'Sullivan GC; Shanahan F
Ann N Y Acad Sci; 2000 Jun; 910():178-92; discussion 193-5. PubMed ID: 10911913
[TBL] [Abstract][Full Text] [Related]
11. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer.
Bennett MW; O'connell J; O'sullivan GC; Roche D; Brady C; Kelly J; Collins JK; Shanahan F
Gut; 1999 Feb; 44(2):156-62. PubMed ID: 9895372
[TBL] [Abstract][Full Text] [Related]
12. CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice.
Behrens CK; Igney FH; Arnold B; Möller P; Krammer PH
J Immunol; 2001 Mar; 166(5):3240-7. PubMed ID: 11207278
[TBL] [Abstract][Full Text] [Related]
13. Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack.
O'Connell J; Bennett MW; O'Sullivan GC; Collins JK; Shanahan F
Dis Esophagus; 1999; 12(2):83-9. PubMed ID: 10466039
[TBL] [Abstract][Full Text] [Related]
14. Tumor expression of Fas ligand (CD95L) and the consequences.
Walker PR; Saas P; Dietrich PY
Curr Opin Immunol; 1998 Oct; 10(5):564-72. PubMed ID: 9794830
[TBL] [Abstract][Full Text] [Related]
15. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
Ryan AE; Shanahan F; O'Connell J; Houston AM
Cancer Res; 2005 Nov; 65(21):9817-23. PubMed ID: 16267003
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma.
Uzzo RG; Rayman P; Kolenko V; Clark PE; Bloom T; Ward AM; Molto L; Tannenbaum C; Worford LJ; Bukowski R; Tubbs R; Hsi ED; Bander NH; Novick AC; Finke JH
Clin Cancer Res; 1999 May; 5(5):1219-29. PubMed ID: 10353760
[TBL] [Abstract][Full Text] [Related]
17. Fas (APO-1/CD95) ligand and Fas expression in renal cell carcinomas: correlation with the prognostic factors.
Kim YS; Kim KH; Choi JA; Lee JH; Kim HK; Won NH; Kim I
Arch Pathol Lab Med; 2000 May; 124(5):687-93. PubMed ID: 10782148
[TBL] [Abstract][Full Text] [Related]
18. Suppression of FasL expression in tumor cells and preventing TNF-induced apoptosis was better for immune cells survival.
Xu G; Zhang J
J Cancer Res Clin Oncol; 2008 Oct; 134(10):1043-9. PubMed ID: 18461366
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand.
von Bernstorff W; Spanjaard RA; Chan AK; Lockhart DC; Sadanaga N; Wood I; Peiper M; Goedegebuure PS; Eberlein TJ
Surgery; 1999 Jan; 125(1):73-84. PubMed ID: 9889801
[TBL] [Abstract][Full Text] [Related]
20. Increased Fas ligand expression by T cells and tumour cells in the progression of actinic keratosis to squamous cell carcinoma.
Satchell AC; Barnetson RS; Halliday GM
Br J Dermatol; 2004 Jul; 151(1):42-9. PubMed ID: 15270871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
